Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4302 | 0.75 | POLB (0.44) | ALDH1A1POLBHTTL3MBTL1CYP3A4 | |
| SCHEMBL3072382 | 0.72 | LMNA (0.35) | ALDH1A1POLBHTTLMNAMAPT | |
| SCHEMBL3084401 | 0.70 | TP53 (0.36) | HTTLMNAL3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL3097410 | 0.69 | LTA4H (0.50) | ALDH1A1POLBHTTLMNAMAPT | |
| SCHEMBL3095270 | 0.68 | SLC6A4 (0.38) | ALDH1A1LMNAMAPTHPGDMEN1 | |
| SCHEMBL3082324 | 0.67 | TOP2A (0.37) | ALDH1A1LMNAL3MBTL1MEN1KMT2A | |
| SCHEMBL8991864 | 0.66 | MAPK1 (0.47) | ALDH1A1HTTLMNAL3MBTL1CTSB | |
| SCHEMBL9334108 | 0.66 | TSHR (0.31) | TSHR | |
| SCHEMBL8995181 | 0.66 | — | — | |
| SCHEMBL4612770 | 0.65 | CYP1A2 (0.36) | ALDH1A1MAPTL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2021-06-29 | — | — | US | claimed |
| US-20200109110-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-04-09 | — | — | US | claimed |
| EP-3050873-B1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-09-13 | — | — | EP | claimed |
| EP-3050873-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-08-03 | — | — | EP | claimed |
| US-8450367-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-05-28 | — | — | US | claimed |
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200109110-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-04-09 | — | — | US | disclosed |
| US-10287243-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3050873-B1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-9663460-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170050925-A9 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2017-02-23 | — | — | US | disclosed |
| EP-3050873-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2651893-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20130252984-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130237552-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130190338-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130165460-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8450367-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012082566-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050925-A9 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885POLB 3493/4885HTT 4321/4885 |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885POLB 3493/4885HTT 4321/4885 |
| US-20130190338-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885POLB 3493/4885HTT 4321/4885 |
| US-20130165460-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885POLB 3493/4885HTT 4321/4885 |
| US-20130237552-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885POLB 3493/4885HTT 4321/4885 |
| US-20200109110-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885POLB 3493/4885HTT 4321/4885 |
| US-20130252984-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885POLB 3493/4885HTT 4321/4885 |
| US-10287243-B2 | Sulfur derivatives as chemokine receptor modulators | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885POLB 3493/4885HTT 4321/4885 |
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885POLB 3493/4885HTT 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.